Brain MRI abnormalities in tuberous sclerosis complex before and after treatment

Abstract

Tuberous sclerosis is a genetic disease whose transmission is autosomal dominant, which in addition to the central nervous system may affect one or more other vital organs with varying severity, hence its current name is TSC. The aim of this study was to evaluate the brain findings in MRI of tuberous sclerosis patients before and after drug treatment. Materials and Methods: In this single-blind randomized clinical trial study, 30 patients with tuberculosis sclerosis diagnosed were taken from a pediatric clinic. Of these, 17 patients (56.7%) had SEGA findings in their initial MRI and were selected for intervention. Everolimus was started at an initial dose of 3 mg/m2 daily for patients and after 6 months of treatment, patients underwent re-MRI (Siemens MRI Machine, 1.5 Tesla). After the intervention, 2 patients were excluded from the study due to drug side effects and one patient was excluded from the study due to unwillingness to continue, and finally 14 patients were examined. Results: The use of Everolimus treatment has resulted in a reduction in the volume of SEGA after treatment for at least 6 months. However, the effects of this drug in the present study seem to be more dependent on the initial volume of SEGA, so that in the present study in larger SEGAs we have seen a therapeutic response. However, the effects of this drug in the present study seem to be more dependent on the initial volume of SEGA, so that the average volume of SEGA in patients without response to treatment was 0.48 cm3 and in patients with response to treatment was 2.5 cm3. That is, the higher the volume of SEGA, the greater the likelihood of a therapeutic response.